Bausch Health Companies (BHC) Raised to Hold at ValuEngine

ValuEngine upgraded shares of Bausch Health Companies (NYSE:BHC) from a sell rating to a hold rating in a report released on Tuesday morning.

A number of other analysts have also recently weighed in on the stock. Morgan Stanley upgraded shares of Bausch Health Companies from an equal weight rating to an overweight rating and set a $32.00 target price for the company in a report on Monday, November 5th. HC Wainwright set a $25.00 target price on shares of Bausch Health Companies and gave the stock a hold rating in a report on Monday, October 15th. Mizuho restated a buy rating and set a $35.00 target price on shares of Bausch Health Companies in a report on Monday, October 8th. Royal Bank of Canada set a $30.00 target price on shares of Bausch Health Companies and gave the stock a hold rating in a report on Monday, October 8th. Finally, Zacks Investment Research cut shares of Bausch Health Companies from a buy rating to a hold rating in a report on Thursday, October 4th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $27.55.

Shares of Bausch Health Companies stock traded down $0.09 on Tuesday, hitting $27.20. The company had a trading volume of 3,898,414 shares, compared to its average volume of 4,904,969. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.14 and a quick ratio of 0.89. The stock has a market capitalization of $9.48 billion, a PE ratio of 7.10, a price-to-earnings-growth ratio of 0.37 and a beta of -0.28. Bausch Health Companies has a 52 week low of $13.86 and a 52 week high of $28.45.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.84 by $0.31. The firm had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.09 billion. Bausch Health Companies had a negative net margin of 40.41% and a positive return on equity of 32.19%. The firm’s revenue was down 3.7% compared to the same quarter last year. On average, analysts forecast that Bausch Health Companies will post 3.7 earnings per share for the current fiscal year.

In related news, EVP Christina Ackermann sold 19,946 shares of the company’s stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total value of $498,251.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joseph C. Papa purchased 30,000 shares of Bausch Health Companies stock in a transaction that occurred on Friday, September 14th. The stock was purchased at an average price of $22.32 per share, with a total value of $669,600.00. The disclosure for this purchase can be found here. Insiders have purchased 165,000 shares of company stock valued at $3,890,700 over the last 90 days. 11.54% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of BHC. Tobam purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $13,886,000. Point View Wealth Management Inc. purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $1,132,000. Private Management Group Inc. purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $28,474,000. Van ECK Associates Corp purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $11,494,000. Finally, Marshall Wace LLP purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $2,974,000. Institutional investors and hedge funds own 42.90% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Article: Closed-End Mutual Funds (CEFs)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit